| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 118 | 2022 | 1011 | 16.620 |
Why?
|
| Liver Neoplasms | 130 | 2022 | 4557 | 9.370 |
Why?
|
| Colorectal Neoplasms | 70 | 2022 | 3578 | 4.820 |
Why?
|
| Postoperative Complications | 50 | 2021 | 5542 | 4.010 |
Why?
|
| Portal Vein | 18 | 2020 | 355 | 3.670 |
Why?
|
| Pancreaticoduodenectomy | 21 | 2020 | 690 | 3.170 |
Why?
|
| Pancreatectomy | 22 | 2020 | 652 | 2.630 |
Why?
|
| Perioperative Care | 13 | 2021 | 451 | 2.550 |
Why?
|
| Embolization, Therapeutic | 15 | 2020 | 551 | 2.520 |
Why?
|
| Quality Improvement | 13 | 2021 | 851 | 2.480 |
Why?
|
| Bile Duct Neoplasms | 13 | 2021 | 493 | 2.420 |
Why?
|
| Surgical Oncology | 8 | 2020 | 190 | 2.230 |
Why?
|
| Liver | 22 | 2021 | 2961 | 2.220 |
Why?
|
| Surgical Procedures, Operative | 11 | 2021 | 383 | 2.120 |
Why?
|
| Recovery of Function | 7 | 2019 | 703 | 1.920 |
Why?
|
| General Surgery | 4 | 2019 | 326 | 1.800 |
Why?
|
| Pain, Postoperative | 10 | 2021 | 610 | 1.770 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2018 | 334 | 1.740 |
Why?
|
| Cholangiocarcinoma | 11 | 2021 | 493 | 1.690 |
Why?
|
| Bile Ducts | 4 | 2018 | 113 | 1.640 |
Why?
|
| Patient Safety | 6 | 2021 | 649 | 1.560 |
Why?
|
| Survival Rate | 78 | 2022 | 12221 | 1.550 |
Why?
|
| Gallbladder Neoplasms | 7 | 2018 | 245 | 1.480 |
Why?
|
| Venous Thromboembolism | 5 | 2019 | 335 | 1.470 |
Why?
|
| Humans | 278 | 2022 | 261506 | 1.460 |
Why?
|
| Klatskin Tumor | 4 | 2018 | 29 | 1.430 |
Why?
|
| Preoperative Care | 13 | 2019 | 1529 | 1.420 |
Why?
|
| Liver Transplantation | 17 | 2018 | 1112 | 1.410 |
Why?
|
| Cholecystectomy | 5 | 2021 | 107 | 1.400 |
Why?
|
| Middle Aged | 169 | 2021 | 86204 | 1.400 |
Why?
|
| Sarcopenia | 3 | 2020 | 110 | 1.390 |
Why?
|
| Quality Indicators, Health Care | 4 | 2019 | 348 | 1.380 |
Why?
|
| Carcinoma, Hepatocellular | 21 | 2020 | 2027 | 1.370 |
Why?
|
| Aged | 151 | 2021 | 70117 | 1.340 |
Why?
|
| Biliary Tract Surgical Procedures | 3 | 2018 | 42 | 1.330 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2019 | 167 | 1.320 |
Why?
|
| Pancreatic Neoplasms | 29 | 2019 | 5061 | 1.290 |
Why?
|
| Health Expenditures | 3 | 2018 | 211 | 1.290 |
Why?
|
| Postoperative Care | 5 | 2019 | 739 | 1.290 |
Why?
|
| Male | 179 | 2021 | 123000 | 1.230 |
Why?
|
| Female | 192 | 2022 | 141928 | 1.210 |
Why?
|
| Neoplasm Staging | 45 | 2020 | 13658 | 1.190 |
Why?
|
| Aged, 80 and over | 87 | 2020 | 29902 | 1.170 |
Why?
|
| Laparoscopy | 11 | 2018 | 1225 | 1.110 |
Why?
|
| Adult | 129 | 2022 | 77950 | 1.090 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2022 | 10035 | 1.090 |
Why?
|
| Treatment Outcome | 77 | 2021 | 32848 | 1.070 |
Why?
|
| Bile Duct Diseases | 3 | 2014 | 45 | 1.050 |
Why?
|
| Analgesics, Opioid | 9 | 2021 | 1371 | 1.010 |
Why?
|
| Patient Readmission | 5 | 2018 | 548 | 1.000 |
Why?
|
| Prognosis | 67 | 2022 | 21713 | 1.000 |
Why?
|
| Early Ambulation | 3 | 2019 | 22 | 1.000 |
Why?
|
| Multivariate Analysis | 25 | 2019 | 4298 | 0.990 |
Why?
|
| Neoplasms | 19 | 2022 | 15193 | 0.980 |
Why?
|
| Follow-Up Studies | 50 | 2021 | 14889 | 0.970 |
Why?
|
| Liver Failure | 4 | 2016 | 140 | 0.970 |
Why?
|
| Clinical Competence | 4 | 2019 | 1270 | 0.970 |
Why?
|
| Liver Regeneration | 7 | 2017 | 134 | 0.960 |
Why?
|
| Intraoperative Complications | 3 | 2019 | 301 | 0.940 |
Why?
|
| Blood Transfusion | 6 | 2018 | 583 | 0.900 |
Why?
|
| Risk Factors | 45 | 2020 | 17523 | 0.900 |
Why?
|
| Fluid Therapy | 4 | 2019 | 182 | 0.880 |
Why?
|
| Elective Surgical Procedures | 4 | 2019 | 250 | 0.860 |
Why?
|
| Adenocarcinoma | 21 | 2019 | 7789 | 0.860 |
Why?
|
| Neoadjuvant Therapy | 30 | 2021 | 4975 | 0.860 |
Why?
|
| Surgeons | 6 | 2021 | 519 | 0.850 |
Why?
|
| Retrospective Studies | 94 | 2022 | 37905 | 0.830 |
Why?
|
| Catheter Ablation | 7 | 2018 | 620 | 0.830 |
Why?
|
| Jejunostomy | 3 | 2017 | 52 | 0.820 |
Why?
|
| Inventions | 1 | 2021 | 37 | 0.810 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2021 | 1303 | 0.790 |
Why?
|
| Postoperative Hemorrhage | 2 | 2013 | 162 | 0.790 |
Why?
|
| Delivery of Health Care | 4 | 2021 | 860 | 0.760 |
Why?
|
| Reoperation | 9 | 2018 | 1382 | 0.750 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2021 | 799 | 0.740 |
Why?
|
| Medicare | 5 | 2019 | 860 | 0.740 |
Why?
|
| Surgical Wound Infection | 4 | 2016 | 450 | 0.740 |
Why?
|
| Pancreatic Fistula | 5 | 2018 | 99 | 0.730 |
Why?
|
| Propensity Score | 8 | 2022 | 750 | 0.730 |
Why?
|
| Surgical Equipment | 1 | 2019 | 17 | 0.730 |
Why?
|
| Analgesia, Epidural | 3 | 2018 | 102 | 0.730 |
Why?
|
| Patient Selection | 16 | 2020 | 2055 | 0.720 |
Why?
|
| Metastasectomy | 7 | 2020 | 200 | 0.710 |
Why?
|
| Goals | 2 | 2022 | 185 | 0.700 |
Why?
|
| ras Proteins | 7 | 2020 | 770 | 0.700 |
Why?
|
| Critical Pathways | 3 | 2021 | 149 | 0.690 |
Why?
|
| Length of Stay | 12 | 2022 | 1900 | 0.690 |
Why?
|
| Organizational Culture | 1 | 2020 | 106 | 0.690 |
Why?
|
| Health Care Costs | 5 | 2019 | 674 | 0.680 |
Why?
|
| Specialties, Surgical | 2 | 2018 | 137 | 0.670 |
Why?
|
| Genes, ras | 5 | 2021 | 667 | 0.670 |
Why?
|
| Datasets as Topic | 1 | 2019 | 181 | 0.670 |
Why?
|
| Young Adult | 43 | 2020 | 21445 | 0.670 |
Why?
|
| United States | 34 | 2020 | 15433 | 0.650 |
Why?
|
| Liver Diseases | 5 | 2018 | 574 | 0.650 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 160 | 0.650 |
Why?
|
| Patient Care Bundles | 1 | 2018 | 30 | 0.650 |
Why?
|
| Carcinoma, Pancreatic Ductal | 9 | 2019 | 1724 | 0.640 |
Why?
|
| Fellowships and Scholarships | 2 | 2019 | 390 | 0.640 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 500 | 0.640 |
Why?
|
| Vascular Surgical Procedures | 4 | 2018 | 655 | 0.640 |
Why?
|
| Gastrectomy | 3 | 2015 | 451 | 0.630 |
Why?
|
| Cancer Care Facilities | 2 | 2019 | 884 | 0.620 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 309 | 0.610 |
Why?
|
| Quality of Health Care | 3 | 2020 | 621 | 0.610 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2017 | 59 | 0.600 |
Why?
|
| Colectomy | 7 | 2017 | 288 | 0.600 |
Why?
|
| Lymph Node Excision | 9 | 2020 | 1959 | 0.590 |
Why?
|
| Ligation | 5 | 2017 | 193 | 0.590 |
Why?
|
| Chi-Square Distribution | 11 | 2017 | 1323 | 0.590 |
Why?
|
| Herniorrhaphy | 1 | 2019 | 169 | 0.590 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 292 | 0.590 |
Why?
|
| Internship and Residency | 3 | 2019 | 1375 | 0.590 |
Why?
|
| Esophagectomy | 3 | 2017 | 911 | 0.580 |
Why?
|
| End Stage Liver Disease | 2 | 2016 | 170 | 0.580 |
Why?
|
| Abdominal Neoplasms | 4 | 2019 | 231 | 0.580 |
Why?
|
| Patient Discharge | 6 | 2021 | 661 | 0.570 |
Why?
|
| Intraabdominal Infections | 1 | 2016 | 4 | 0.570 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2016 | 600 | 0.570 |
Why?
|
| Time Factors | 23 | 2019 | 12926 | 0.570 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 77 | 0.570 |
Why?
|
| Mesenteric Veins | 4 | 2018 | 73 | 0.570 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 4320 | 0.570 |
Why?
|
| Oncologists | 1 | 2018 | 134 | 0.570 |
Why?
|
| Prospective Studies | 29 | 2021 | 12873 | 0.560 |
Why?
|
| Patient Handoff | 1 | 2016 | 39 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2021 | 15862 | 0.560 |
Why?
|
| Databases, Factual | 11 | 2019 | 2218 | 0.560 |
Why?
|
| Abdomen, Acute | 1 | 2016 | 36 | 0.550 |
Why?
|
| Logistic Models | 11 | 2019 | 3441 | 0.550 |
Why?
|
| Wound Closure Techniques | 1 | 2016 | 28 | 0.550 |
Why?
|
| Suture Techniques | 2 | 2015 | 319 | 0.550 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 270 | 0.550 |
Why?
|
| Education, Medical, Graduate | 3 | 2019 | 671 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2019 | 7551 | 0.540 |
Why?
|
| Cardia | 1 | 2015 | 39 | 0.540 |
Why?
|
| Incidence | 13 | 2020 | 5673 | 0.540 |
Why?
|
| Surgical Wound | 1 | 2016 | 48 | 0.530 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2017 | 275 | 0.530 |
Why?
|
| Gastroenterology | 1 | 2018 | 195 | 0.530 |
Why?
|
| Sports | 1 | 2016 | 80 | 0.520 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 2403 | 0.520 |
Why?
|
| Texas | 15 | 2020 | 6311 | 0.520 |
Why?
|
| Analgesics | 2 | 2017 | 390 | 0.510 |
Why?
|
| Chemotherapy, Adjuvant | 21 | 2019 | 3890 | 0.510 |
Why?
|
| Laparotomy | 1 | 2016 | 211 | 0.510 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 321 | 0.510 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 343 | 0.500 |
Why?
|
| Ambulatory Care | 1 | 2019 | 554 | 0.500 |
Why?
|
| Cross Infection | 1 | 2019 | 544 | 0.500 |
Why?
|
| Drug Prescriptions | 4 | 2021 | 289 | 0.500 |
Why?
|
| Risk Adjustment | 2 | 2014 | 83 | 0.490 |
Why?
|
| Age Factors | 12 | 2018 | 5377 | 0.490 |
Why?
|
| Clinical Coding | 1 | 2014 | 28 | 0.480 |
Why?
|
| Tissue Adhesions | 1 | 2014 | 60 | 0.480 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 461 | 0.470 |
Why?
|
| Fibrinolytic Agents | 2 | 2013 | 324 | 0.470 |
Why?
|
| Mutation | 24 | 2021 | 15179 | 0.470 |
Why?
|
| Intention | 1 | 2014 | 109 | 0.460 |
Why?
|
| Carcinoma | 2 | 2015 | 2578 | 0.460 |
Why?
|
| Communication | 2 | 2018 | 876 | 0.460 |
Why?
|
| Adrenalectomy | 2 | 2017 | 188 | 0.460 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 399 | 0.450 |
Why?
|
| Decision Support Techniques | 3 | 2012 | 622 | 0.450 |
Why?
|
| Adolescent | 30 | 2018 | 31252 | 0.440 |
Why?
|
| Neuroendocrine Tumors | 5 | 2018 | 634 | 0.440 |
Why?
|
| Hospitalization | 3 | 2018 | 2083 | 0.440 |
Why?
|
| Hepatic Insufficiency | 4 | 2017 | 34 | 0.440 |
Why?
|
| Smad4 Protein | 3 | 2019 | 196 | 0.440 |
Why?
|
| Pancreatic Ducts | 2 | 2017 | 122 | 0.430 |
Why?
|
| Documentation | 1 | 2014 | 207 | 0.430 |
Why?
|
| Antibiotic Prophylaxis | 4 | 2019 | 181 | 0.430 |
Why?
|
| Electronic Health Records | 2 | 2019 | 929 | 0.420 |
Why?
|
| Decision Making | 3 | 2020 | 1287 | 0.420 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 918 | 0.410 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2020 | 630 | 0.410 |
Why?
|
| Risk Assessment | 15 | 2019 | 6869 | 0.410 |
Why?
|
| Lung Diseases | 1 | 2017 | 717 | 0.410 |
Why?
|
| Antineoplastic Agents | 15 | 2020 | 14289 | 0.410 |
Why?
|
| Fluorouracil | 10 | 2019 | 1944 | 0.410 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2017 | 489 | 0.410 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 421 | 0.410 |
Why?
|
| Lymphatic Metastasis | 13 | 2019 | 4844 | 0.400 |
Why?
|
| Odds Ratio | 7 | 2017 | 2316 | 0.400 |
Why?
|
| Patient Compliance | 1 | 2015 | 667 | 0.390 |
Why?
|
| Disease-Free Survival | 20 | 2019 | 10001 | 0.390 |
Why?
|
| GTP Phosphohydrolases | 4 | 2019 | 336 | 0.390 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2013 | 172 | 0.390 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2017 | 7702 | 0.380 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2013 | 223 | 0.380 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 3 | 2008 | 169 | 0.380 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2019 | 1331 | 0.360 |
Why?
|
| Health Status | 1 | 2013 | 590 | 0.360 |
Why?
|
| Tissue and Organ Procurement | 2 | 2010 | 233 | 0.360 |
Why?
|
| Survival Analysis | 17 | 2018 | 9180 | 0.360 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 739 | 0.360 |
Why?
|
| Palliative Care | 3 | 2016 | 2037 | 0.360 |
Why?
|
| Cohort Studies | 18 | 2022 | 9244 | 0.360 |
Why?
|
| Clinical Protocols | 3 | 2019 | 467 | 0.350 |
Why?
|
| Radiopharmaceuticals | 3 | 2019 | 1301 | 0.350 |
Why?
|
| Proportional Hazards Models | 16 | 2020 | 4988 | 0.350 |
Why?
|
| Pipecolic Acids | 1 | 2009 | 13 | 0.350 |
Why?
|
| Waiting Lists | 3 | 2007 | 263 | 0.350 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2012 | 328 | 0.340 |
Why?
|
| Feasibility Studies | 5 | 2019 | 2292 | 0.340 |
Why?
|
| Organ Size | 6 | 2017 | 690 | 0.330 |
Why?
|
| Yttrium Radioisotopes | 1 | 2009 | 178 | 0.320 |
Why?
|
| Surgery Department, Hospital | 1 | 2008 | 30 | 0.320 |
Why?
|
| Stents | 3 | 2018 | 1096 | 0.320 |
Why?
|
| Stomach Neoplasms | 3 | 2015 | 2278 | 0.320 |
Why?
|
| Inflammation | 2 | 2017 | 2522 | 0.320 |
Why?
|
| Exercise | 1 | 2016 | 1183 | 0.320 |
Why?
|
| Predictive Value of Tests | 10 | 2019 | 4892 | 0.320 |
Why?
|
| Anticoagulants | 2 | 2016 | 787 | 0.320 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 6009 | 0.310 |
Why?
|
| Testicular Neoplasms | 1 | 2012 | 529 | 0.310 |
Why?
|
| Melanoma | 6 | 2008 | 5317 | 0.310 |
Why?
|
| Hemangioendothelioma | 1 | 2007 | 35 | 0.300 |
Why?
|
| Graft Survival | 7 | 2013 | 1062 | 0.300 |
Why?
|
| Tissue Donors | 2 | 2009 | 769 | 0.300 |
Why?
|
| Thoracic Neoplasms | 1 | 2010 | 337 | 0.300 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 5687 | 0.300 |
Why?
|
| Hyperthermia, Induced | 3 | 2008 | 510 | 0.290 |
Why?
|
| Heparin | 1 | 2009 | 360 | 0.290 |
Why?
|
| Organoplatinum Compounds | 6 | 2017 | 702 | 0.290 |
Why?
|
| Algorithms | 4 | 2020 | 3890 | 0.280 |
Why?
|
| Incidental Findings | 3 | 2017 | 272 | 0.280 |
Why?
|
| Pain Management | 4 | 2020 | 668 | 0.280 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2017 | 145 | 0.270 |
Why?
|
| Cautery | 1 | 2005 | 9 | 0.270 |
Why?
|
| Gastritis | 1 | 2009 | 373 | 0.270 |
Why?
|
| Hypertrophy | 4 | 2020 | 162 | 0.270 |
Why?
|
| Antibodies | 1 | 2009 | 838 | 0.270 |
Why?
|
| Hemostatic Techniques | 1 | 2005 | 38 | 0.260 |
Why?
|
| Ultrasonic Therapy | 1 | 2005 | 55 | 0.260 |
Why?
|
| Chemoradiotherapy, Adjuvant | 7 | 2018 | 565 | 0.260 |
Why?
|
| Ablation Techniques | 2 | 2016 | 148 | 0.250 |
Why?
|
| Combined Modality Therapy | 10 | 2020 | 8865 | 0.250 |
Why?
|
| Carcinoma, Lobular | 2 | 2020 | 611 | 0.250 |
Why?
|
| Quality Assurance, Health Care | 2 | 2019 | 585 | 0.240 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2195 | 0.240 |
Why?
|
| Transfusion Reaction | 2 | 2015 | 102 | 0.240 |
Why?
|
| Pneumonectomy | 4 | 2018 | 831 | 0.240 |
Why?
|
| Skin Neoplasms | 5 | 2008 | 4654 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 3552 | 0.240 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 846 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2019 | 6207 | 0.230 |
Why?
|
| Habits | 2 | 2020 | 36 | 0.230 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2020 | 521 | 0.230 |
Why?
|
| Preoperative Period | 4 | 2019 | 344 | 0.220 |
Why?
|
| Morbidity | 5 | 2022 | 397 | 0.220 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2020 | 1415 | 0.220 |
Why?
|
| Membrane Proteins | 4 | 2019 | 2819 | 0.210 |
Why?
|
| Thrombosis | 1 | 2009 | 781 | 0.210 |
Why?
|
| Thyroid Neoplasms | 2 | 2019 | 1866 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.210 |
Why?
|
| Drainage | 3 | 2016 | 416 | 0.210 |
Why?
|
| Gastroscopy | 2 | 2014 | 134 | 0.210 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2015 | 297 | 0.210 |
Why?
|
| Leucovorin | 4 | 2019 | 332 | 0.200 |
Why?
|
| Radiation Injuries | 1 | 2009 | 1411 | 0.200 |
Why?
|
| Peritoneal Neoplasms | 2 | 2019 | 821 | 0.200 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 1202 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2021 | 1390 | 0.200 |
Why?
|
| Biomarkers, Tumor | 12 | 2021 | 10331 | 0.200 |
Why?
|
| Microspheres | 2 | 2013 | 210 | 0.190 |
Why?
|
| Health Facilities | 1 | 2021 | 79 | 0.190 |
Why?
|
| Intraoperative Period | 2 | 2013 | 246 | 0.190 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2021 | 68 | 0.190 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2020 | 98 | 0.190 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 158 | 0.190 |
Why?
|
| Streptozocin | 2 | 2018 | 75 | 0.180 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 1341 | 0.180 |
Why?
|
| Hospital Mortality | 5 | 2022 | 1274 | 0.180 |
Why?
|
| Operative Time | 3 | 2020 | 217 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 98 | 0.180 |
Why?
|
| Pancreas | 2 | 2021 | 718 | 0.180 |
Why?
|
| Chemoradiotherapy | 6 | 2019 | 1946 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 4 | 2017 | 945 | 0.180 |
Why?
|
| Camptothecin | 3 | 2012 | 517 | 0.180 |
Why?
|
| Data Collection | 1 | 2022 | 620 | 0.180 |
Why?
|
| Common Bile Duct | 1 | 2019 | 27 | 0.170 |
Why?
|
| Body Composition | 2 | 2020 | 595 | 0.170 |
Why?
|
| Analysis of Variance | 4 | 2016 | 2307 | 0.170 |
Why?
|
| Eligibility Determination | 1 | 2019 | 77 | 0.170 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2019 | 51 | 0.170 |
Why?
|
| Benchmarking | 2 | 2019 | 273 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2015 | 551 | 0.170 |
Why?
|
| Genital Neoplasms, Female | 2 | 2016 | 735 | 0.170 |
Why?
|
| Anastomotic Leak | 1 | 2019 | 71 | 0.170 |
Why?
|
| Evidence-Based Practice | 1 | 2019 | 117 | 0.160 |
Why?
|
| Comorbidity | 2 | 2016 | 2352 | 0.160 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2019 | 94 | 0.160 |
Why?
|
| Historically Controlled Study | 1 | 2018 | 3 | 0.160 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 550 | 0.160 |
Why?
|
| Consensus | 3 | 2020 | 978 | 0.160 |
Why?
|
| Academic Medical Centers | 3 | 2016 | 672 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 419 | 0.160 |
Why?
|
| Inpatients | 2 | 2022 | 678 | 0.150 |
Why?
|
| Lipoxins | 1 | 2017 | 20 | 0.150 |
Why?
|
| CA-19-9 Antigen | 2 | 2019 | 144 | 0.150 |
Why?
|
| Vascular Patency | 1 | 2018 | 218 | 0.150 |
Why?
|
| Water-Electrolyte Balance | 1 | 2017 | 104 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 190 | 0.150 |
Why?
|
| Muscular Atrophy | 1 | 2018 | 105 | 0.150 |
Why?
|
| Standard of Care | 1 | 2019 | 243 | 0.150 |
Why?
|
| Costs and Cost Analysis | 3 | 2022 | 306 | 0.150 |
Why?
|
| Pandemics | 3 | 2022 | 1559 | 0.150 |
Why?
|
| Consensus Development Conferences as Topic | 3 | 2013 | 75 | 0.150 |
Why?
|
| Liver Function Tests | 1 | 2017 | 173 | 0.150 |
Why?
|
| Teratoma | 1 | 2019 | 236 | 0.150 |
Why?
|
| Lung Neoplasms | 6 | 2018 | 11538 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 8 | 2017 | 3981 | 0.150 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 79 | 0.150 |
Why?
|
| Postoperative Period | 5 | 2019 | 665 | 0.150 |
Why?
|
| Bile | 2 | 2013 | 81 | 0.140 |
Why?
|
| Perioperative Period | 1 | 2017 | 155 | 0.140 |
Why?
|
| Public Health | 1 | 2019 | 299 | 0.140 |
Why?
|
| Reperfusion Injury | 1 | 2017 | 145 | 0.140 |
Why?
|
| Somatostatin | 1 | 2017 | 114 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 499 | 0.140 |
Why?
|
| Hospital Costs | 2 | 2015 | 228 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2019 | 574 | 0.140 |
Why?
|
| Hepatic Duct, Common | 1 | 2016 | 16 | 0.140 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 126 | 0.140 |
Why?
|
| Splenic Vein | 1 | 2015 | 17 | 0.140 |
Why?
|
| Liver Abscess | 1 | 2016 | 36 | 0.140 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2016 | 255 | 0.140 |
Why?
|
| Insulinoma | 1 | 2016 | 55 | 0.140 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 232 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2019 | 1391 | 0.140 |
Why?
|
| Outpatients | 1 | 2019 | 462 | 0.140 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 748 | 0.140 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 183 | 0.140 |
Why?
|
| Hydrocortisone | 1 | 2017 | 388 | 0.140 |
Why?
|
| Cholangitis | 1 | 2016 | 48 | 0.140 |
Why?
|
| Ampulla of Vater | 1 | 2017 | 155 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4638 | 0.140 |
Why?
|
| Splenic Artery | 1 | 2015 | 50 | 0.140 |
Why?
|
| Hormones | 1 | 2017 | 266 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 429 | 0.130 |
Why?
|
| Colorectal Surgery | 1 | 2015 | 32 | 0.130 |
Why?
|
| Niacinamide | 2 | 2017 | 421 | 0.130 |
Why?
|
| Music | 1 | 2015 | 36 | 0.130 |
Why?
|
| Quality of Life | 2 | 2022 | 4532 | 0.130 |
Why?
|
| Sex Factors | 3 | 2015 | 2139 | 0.130 |
Why?
|
| Observer Variation | 1 | 2017 | 671 | 0.130 |
Why?
|
| Workflow | 1 | 2016 | 275 | 0.130 |
Why?
|
| Neoplasm Metastasis | 6 | 2019 | 5112 | 0.130 |
Why?
|
| Voriconazole | 1 | 2016 | 108 | 0.130 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2017 | 337 | 0.130 |
Why?
|
| Anesthesia | 1 | 2019 | 296 | 0.130 |
Why?
|
| Professional Role | 1 | 2015 | 78 | 0.130 |
Why?
|
| Eating | 1 | 2017 | 421 | 0.130 |
Why?
|
| Extremities | 3 | 2008 | 303 | 0.130 |
Why?
|
| Tumor Burden | 5 | 2021 | 1987 | 0.130 |
Why?
|
| Medical Staff, Hospital | 1 | 2015 | 118 | 0.130 |
Why?
|
| Doxorubicin | 3 | 2018 | 3005 | 0.130 |
Why?
|
| Lymph Nodes | 4 | 2020 | 2967 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 2488 | 0.130 |
Why?
|
| Blood Vessels | 1 | 2016 | 217 | 0.130 |
Why?
|
| Disease Progression | 7 | 2019 | 6682 | 0.130 |
Why?
|
| Operating Rooms | 1 | 2015 | 122 | 0.120 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2015 | 141 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1382 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 481 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 384 | 0.120 |
Why?
|
| Stomach | 2 | 2014 | 387 | 0.120 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 1656 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 409 | 0.120 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 2283 | 0.120 |
Why?
|
| Risk Management | 1 | 2015 | 107 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2015 | 495 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.120 |
Why?
|
| Surgical Stapling | 1 | 2013 | 36 | 0.120 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 15694 | 0.120 |
Why?
|
| Child | 13 | 2018 | 29154 | 0.120 |
Why?
|
| Phenylurea Compounds | 2 | 2017 | 580 | 0.120 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2017 | 181 | 0.120 |
Why?
|
| Aspergillosis | 1 | 2016 | 246 | 0.120 |
Why?
|
| Nomograms | 1 | 2016 | 313 | 0.120 |
Why?
|
| Jejunal Neoplasms | 1 | 2013 | 34 | 0.120 |
Why?
|
| beta-Lactams | 1 | 2013 | 53 | 0.120 |
Why?
|
| Deoxycytidine | 5 | 2019 | 1353 | 0.120 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2013 | 39 | 0.120 |
Why?
|
| Spleen | 1 | 2015 | 676 | 0.120 |
Why?
|
| Transplantation, Homologous | 3 | 2009 | 2843 | 0.120 |
Why?
|
| Ileal Neoplasms | 1 | 2013 | 47 | 0.120 |
Why?
|
| Leiomyosarcoma | 1 | 2015 | 223 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 833 | 0.110 |
Why?
|
| Patient Preference | 1 | 2015 | 218 | 0.110 |
Why?
|
| Registries | 4 | 2019 | 2170 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2019 | 1226 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 1216 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 1910 | 0.110 |
Why?
|
| Fatigue | 1 | 2019 | 1239 | 0.110 |
Why?
|
| Diaphragm | 1 | 2014 | 181 | 0.110 |
Why?
|
| Serum Albumin | 1 | 2013 | 257 | 0.110 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2015 | 262 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2017 | 1038 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 212 | 0.110 |
Why?
|
| Foreign Bodies | 1 | 2014 | 145 | 0.110 |
Why?
|
| Margins of Excision | 3 | 2020 | 285 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 2992 | 0.110 |
Why?
|
| Positron-Emission Tomography | 3 | 2016 | 2173 | 0.100 |
Why?
|
| Radiation Protection | 1 | 2013 | 205 | 0.100 |
Why?
|
| Surgical Mesh | 1 | 2013 | 209 | 0.100 |
Why?
|
| Self Report | 1 | 2015 | 756 | 0.100 |
Why?
|
| Sepsis | 2 | 2015 | 652 | 0.100 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2014 | 356 | 0.100 |
Why?
|
| SEER Program | 4 | 2018 | 1000 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2015 | 627 | 0.100 |
Why?
|
| Biopsy | 2 | 2017 | 3443 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2012 | 193 | 0.100 |
Why?
|
| Dyspnea | 1 | 2013 | 416 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2016 | 716 | 0.090 |
Why?
|
| Symptom Assessment | 1 | 2012 | 267 | 0.090 |
Why?
|
| Biological Products | 1 | 2013 | 274 | 0.090 |
Why?
|
| Survival | 1 | 2010 | 177 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2013 | 499 | 0.090 |
Why?
|
| Injections, Intra-Arterial | 1 | 2009 | 62 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2017 | 1154 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2016 | 834 | 0.090 |
Why?
|
| Salpingo-oophorectomy | 2 | 2020 | 50 | 0.090 |
Why?
|
| Colon | 1 | 2013 | 670 | 0.090 |
Why?
|
| Gastric Bypass | 1 | 2009 | 81 | 0.080 |
Why?
|
| New Jersey | 1 | 2008 | 35 | 0.080 |
Why?
|
| Certificate of Need | 1 | 2008 | 8 | 0.080 |
Why?
|
| Survivors | 2 | 2016 | 1031 | 0.080 |
Why?
|
| New York | 1 | 2008 | 104 | 0.080 |
Why?
|
| Coloring Agents | 2 | 2021 | 234 | 0.080 |
Why?
|
| Indocyanine Green | 2 | 2021 | 117 | 0.080 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 705 | 0.080 |
Why?
|
| Florida | 1 | 2008 | 113 | 0.080 |
Why?
|
| Hepatitis C | 2 | 2012 | 524 | 0.080 |
Why?
|
| Transplants | 1 | 2008 | 52 | 0.080 |
Why?
|
| Program Evaluation | 2 | 2021 | 597 | 0.080 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2007 | 16 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 1058 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 4314 | 0.080 |
Why?
|
| Perception | 2 | 2020 | 350 | 0.080 |
Why?
|
| Software | 1 | 2014 | 1321 | 0.080 |
Why?
|
| Enteral Nutrition | 1 | 2009 | 316 | 0.070 |
Why?
|
| Pain | 1 | 2015 | 1658 | 0.070 |
Why?
|
| Sentinel Lymph Node | 2 | 2020 | 216 | 0.070 |
Why?
|
| Patient Dropouts | 1 | 2007 | 88 | 0.070 |
Why?
|
| Child, Preschool | 7 | 2015 | 16273 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2012 | 899 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1945 | 0.070 |
Why?
|
| Atrophy | 2 | 2017 | 261 | 0.070 |
Why?
|
| Bevacizumab | 3 | 2017 | 938 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 4744 | 0.070 |
Why?
|
| Health Care Rationing | 1 | 2007 | 94 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2013 | 2231 | 0.070 |
Why?
|
| Cholangiography | 2 | 2021 | 36 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2007 | 148 | 0.070 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 486 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2011 | 761 | 0.070 |
Why?
|
| Dissection | 2 | 2016 | 156 | 0.070 |
Why?
|
| Biomarkers | 1 | 2017 | 5047 | 0.070 |
Why?
|
| alpha-Fetoproteins | 3 | 2012 | 237 | 0.070 |
Why?
|
| Cetuximab | 1 | 2007 | 472 | 0.070 |
Why?
|
| Hysterectomy | 2 | 2020 | 611 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 698 | 0.070 |
Why?
|
| Anastomosis, Surgical | 2 | 2018 | 371 | 0.070 |
Why?
|
| Demography | 1 | 2007 | 435 | 0.070 |
Why?
|
| Arginine | 1 | 2009 | 500 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 960 | 0.060 |
Why?
|
| Cholestasis | 1 | 2007 | 203 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 1533 | 0.060 |
Why?
|
| Sodium Chloride | 1 | 2005 | 156 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2007 | 246 | 0.060 |
Why?
|
| Melphalan | 2 | 2008 | 834 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 3719 | 0.060 |
Why?
|
| Sarcoma | 1 | 2015 | 1725 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 726 | 0.060 |
Why?
|
| Hospitals | 1 | 2008 | 485 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 3251 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 2006 | 247 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 2370 | 0.060 |
Why?
|
| Cause of Death | 2 | 2016 | 752 | 0.060 |
Why?
|
| Lung | 1 | 2014 | 3151 | 0.060 |
Why?
|
| Neutrophils | 2 | 2017 | 835 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2007 | 834 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2008 | 1529 | 0.050 |
Why?
|
| Cisplatin | 3 | 2014 | 2432 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 5159 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5437 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 1054 | 0.050 |
Why?
|
| Genes, APC | 1 | 2021 | 70 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2014 | 665 | 0.050 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2020 | 83 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2018 | 6100 | 0.050 |
Why?
|
| Mass Screening | 1 | 2009 | 1509 | 0.050 |
Why?
|
| Fluorescence | 1 | 2021 | 195 | 0.050 |
Why?
|
| Harm Reduction | 1 | 2020 | 16 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 980 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 3976 | 0.050 |
Why?
|
| ROC Curve | 2 | 2015 | 1183 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 3472 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2013 | 702 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8873 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2006 | 1171 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 588 | 0.050 |
Why?
|
| Policy Making | 1 | 2020 | 85 | 0.050 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 50 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2009 | 1823 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2020 | 75 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2019 | 1283 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 261 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 275 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 63 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2291 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 2018 | 61 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2019 | 1863 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 205 | 0.040 |
Why?
|
| Cystic Duct | 1 | 2017 | 10 | 0.040 |
Why?
|
| Albumins | 1 | 2019 | 258 | 0.040 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2018 | 168 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 717 | 0.040 |
Why?
|
| Ligaments | 1 | 2017 | 43 | 0.040 |
Why?
|
| Chile | 1 | 2017 | 61 | 0.040 |
Why?
|
| Health Policy | 1 | 2020 | 291 | 0.040 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 108 | 0.040 |
Why?
|
| Obesity | 1 | 2010 | 2884 | 0.040 |
Why?
|
| Government Agencies | 1 | 2016 | 21 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5319 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 2594 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 4758 | 0.040 |
Why?
|
| Duodenum | 1 | 2017 | 149 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 625 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 1090 | 0.040 |
Why?
|
| Canada | 2 | 2007 | 429 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2017 | 240 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 21 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2019 | 486 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2020 | 636 | 0.030 |
Why?
|
| Radiography, Interventional | 1 | 2018 | 305 | 0.030 |
Why?
|
| Endometrium | 1 | 2019 | 470 | 0.030 |
Why?
|
| Thorax | 1 | 2016 | 213 | 0.030 |
Why?
|
| Arthralgia | 1 | 2016 | 89 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 363 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Abdomen | 1 | 2016 | 332 | 0.030 |
Why?
|
| Hypertension, Portal | 1 | 2015 | 124 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 297 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 4367 | 0.030 |
Why?
|
| Video-Assisted Surgery | 1 | 2014 | 28 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2016 | 135 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1392 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 953 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 726 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 941 | 0.030 |
Why?
|
| Attention | 1 | 2015 | 281 | 0.030 |
Why?
|
| Internationality | 1 | 2015 | 208 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2015 | 277 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 213 | 0.030 |
Why?
|
| Radiography | 1 | 2018 | 1904 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2013 | 136 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2013 | 114 | 0.030 |
Why?
|
| Mesentery | 1 | 2013 | 72 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 692 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 669 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2016 | 324 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 226 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 388 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 192 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2086 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 221 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2019 | 1996 | 0.030 |
Why?
|
| Diarrhea | 1 | 2016 | 686 | 0.030 |
Why?
|
| Gadolinium | 1 | 2013 | 164 | 0.030 |
Why?
|
| Decision Trees | 1 | 2012 | 178 | 0.030 |
Why?
|
| Reimbursement Mechanisms | 1 | 2012 | 78 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 289 | 0.030 |
Why?
|
| Endoscopy | 1 | 2014 | 479 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 1270 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 280 | 0.020 |
Why?
|
| Medical Records | 1 | 2012 | 415 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1506 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2015 | 1665 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2014 | 543 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 2012 | 217 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 2315 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2012 | 694 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2015 | 795 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 2518 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2015 | 902 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2012 | 258 | 0.020 |
Why?
|
| Body Weight | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2012 | 397 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7573 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2203 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2013 | 889 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 1335 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2008 | 145 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Hepatitis B, Chronic | 1 | 2009 | 137 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 2927 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2054 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 1678 | 0.020 |
Why?
|
| Living Donors | 1 | 2007 | 171 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2007 | 233 | 0.020 |
Why?
|
| Cadaver | 1 | 2007 | 237 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 231 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 4971 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 1299 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2007 | 310 | 0.020 |
Why?
|
| Contrast Media | 1 | 2013 | 1472 | 0.020 |
Why?
|
| Angiography | 1 | 2007 | 360 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 3842 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 1248 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2014 | 1330 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2009 | 451 | 0.010 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 2104 | 0.010 |
Why?
|
| Infant | 2 | 2007 | 13310 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4849 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 8223 | 0.010 |
Why?
|